These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38091970)

  • 1. Efficacy of Cetuximab Combined with Paclitaxel in Patients with Recurrent Salivary Gland Carcinoma: A Retrospective Observational Study.
    Sato R; Yuasa R; Kumai T; Wakisaka R; Komatsuda H; Kono M; Yamaki H; Ishida Y; Wada T; Takahara M; Katada A
    ORL J Otorhinolaryngol Relat Spec; 2024; 86(1):41-49. PubMed ID: 38091970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
    Suzuki S; Toyoma S; Kawasaki Y; Koizumi K; Iikawa N; Shiina K; Endo T; Abe T; Kouga T; Yamada T
    Medicina (Kaunas); 2021 Oct; 57(11):. PubMed ID: 34833369
    [No Abstract]   [Full Text] [Related]  

  • 3. Weekly Cetuximab and Paclitaxel for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
    Fushimi C; Baba D; Masubuchi T; Yamazaki M; Kitani Y; Kitajima T; Tanaka J; Hanyu K; Tanaka N; Miura K; Tada Y
    In Vivo; 2020; 34(5):2653-2657. PubMed ID: 32871796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01).
    Kim Y; Lee SJ; Lee JY; Lee SH; Sun JM; Park K; An HJ; Cho JY; Kang EJ; Lee HY; Kim J; Keam B; Kim HR; Lee KE; Choi MY; Lee KH; Ahn MJ
    Cancer; 2017 Jun; 123(11):1958-1964. PubMed ID: 28102887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical impact of weekly paclitaxel plus cetuximab is comparable to the EXTREME regimen for recurrent/metastatic head and neck squamous cell carcinoma.
    Motai R; Sawabe M; Kadowaki S; Sasaki E; Nishikawa D; Suzuki H; Beppu S; Terada H; Hanai N
    Int J Clin Oncol; 2021 Jul; 26(7):1188-1195. PubMed ID: 33821363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paclitaxel Plus Cetuximab as 1st Line Chemotherapy in Platinum-Based Chemoradiotherapy-Refractory Patients With Squamous Cell Carcinoma of the Head and Neck.
    Enokida T; Okano S; Fujisawa T; Ueda Y; Uozumi S; Tahara M
    Front Oncol; 2018; 8():339. PubMed ID: 30211118
    [No Abstract]   [Full Text] [Related]  

  • 7. Effectiveness and safety of weekly paclitaxel and cetuximab as a salvage chemotherapy following immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: A multicenter clinical study.
    Wakasaki T; Manako T; Yasumatsu R; Hara H; Toh S; Masuda M; Yamauchi M; Kuratomi Y; Nishimura E; Takeuchi T; Matsuo M; Jiromaru R; Hashimoto K; Komune N; Nakagawa T
    PLoS One; 2022; 17(7):e0271907. PubMed ID: 35901098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy.
    Shirakawa T; Kato K; Nagashima K; Nishikawa A; Sawada R; Takahashi N; Shoji H; Sasaki Y; Honma Y; Iwasa S; Takashima A; Okita N; Hamaguchi T; Yamada Y; Shimada Y
    Cancer Chemother Pharmacol; 2014 Dec; 74(6):1207-15. PubMed ID: 25267597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter Retrospective Study of Weekly Cetuximab Plus Paclitaxel for Recurrent or Metastatic Oral Squamous Cell Carcinoma.
    Naruse T; Yanamoto S; Otsuru M; Yamakawa N; Kirita T; Shintani Y; Matsumura T; Okura M; Sasaki M; Ota Y; Yamada SI; Kurita H; Umeda M;
    Anticancer Res; 2021 Nov; 41(11):5785-5791. PubMed ID: 34732452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study.
    Kurzrock R; Bowles DW; Kang H; Meric-Bernstam F; Hainsworth J; Spigel DR; Bose R; Burris H; Sweeney CJ; Beattie MS; Blotner S; Schulze K; Cuchelkar V; Swanton C
    Ann Oncol; 2020 Mar; 31(3):412-421. PubMed ID: 32067683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.
    Hitt R; Irigoyen A; Cortes-Funes H; Grau JJ; García-Sáenz JA; Cruz-Hernandez JJ;
    Ann Oncol; 2012 Apr; 23(4):1016-22. PubMed ID: 21865152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biweekly administration of cetuximab in Japanese patients with recurrent or metastatic head and neck cancer.
    Tanaka N; Enokida T; Fujisawa T; Okano S; Wada A; Sato M; Tanaka H; Takeshita N; Tahara M
    Int J Clin Oncol; 2022 Nov; 27(11):1669-1674. PubMed ID: 35943644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Efficacy of Cetuximab-Based Salvage Chemotherapy After Checkpoint Inhibitors in Head and Neck Cancer.
    Cabezas-Camarero S; Cabrera-Martín MN; Merino-Menéndez S; Paz-Cabezas M; García-Barberán V; Sáiz-Pardo Sanz M; Iglesias-Moreno M; Alonso-Ovies A; Pérez-Segura P
    Oncologist; 2021 Jun; 26(6):e1018-e1035. PubMed ID: 33751752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination chemotherapy of carboplatin and paclitaxel for advanced/metastatic salivary gland carcinoma patients: differences in responses by different pathological diagnoses.
    Nakano K; Sato Y; Sasaki T; Shimbashi W; Fukushima H; Yonekawa H; Mitani H; Kawabata K; Takahashi S
    Acta Otolaryngol; 2016 Sep; 136(9):948-51. PubMed ID: 27094013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
    Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
    Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carboplatin and Docetaxel in Patients With Salivary Gland Carcinoma: A Retrospective Study.
    Okada T; Saotome T; Nagao T; Masubuchi T; Fushimi C; Matsuki T; Takahashi H; Miura K; Tsukahara K; Tada Y
    In Vivo; 2019; 33(3):843-853. PubMed ID: 31028207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Single-Arm, Prospective, Phase II Study of Cisplatin Plus Weekly Docetaxel as First-Line Therapy in Patients with Metastatic or Recurrent Salivary Gland Cancer.
    Kim HR; Lee SJ; Park S; Jung HA; Lee SH; Jeong HS; Chung MK; Ahn MJ
    Cancer Res Treat; 2022 Jul; 54(3):719-727. PubMed ID: 34727492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in patients with recurrent high-grade neuroendocrine cervical cancer: a Neuroendocrine Cervical Tumor Registry (NeCTuR) study.
    Frumovitz M; Chisholm GB; Jhingran A; Ramalingam P; Flores-Legarreta A; Bhosale P; Gonzales NR; Hillman RT; Salvo G
    Am J Obstet Gynecol; 2023 Apr; 228(4):445.e1-445.e8. PubMed ID: 36516952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retrospective Study of Cisplatin/Carboplatin, 5-Fluorouracil Plus Cetuximab (EXTREME) for Advanced-stage Salivary Gland Cancer.
    Nakano T; Yasumatsu R; Hashimoto K; Kuga R; Hongo T; Yamamoto H; Matsuo M; Wakasaki T; Jiromaru R; Manako T; Toh S; Masuda M; Yamauchi M; Kuratomi Y; Uryu H; Nakashima T; Tamae A; Tanaka R; Taura M; Takeuchi T; Yoshida T; Nakagawa T
    In Vivo; 2022; 36(2):979-984. PubMed ID: 35241559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer.
    Rodriguez CP; Wu QV; Voutsinas J; Fromm JR; Jiang X; Pillarisetty VG; Lee SM; Santana-Davila R; Goulart B; Baik CS; Chow LQM; Eaton K; Martins R
    Clin Cancer Res; 2020 Feb; 26(4):837-845. PubMed ID: 31796519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.